| 1 |
贾宏伟, 熊智灵, 程卯生, 等. 具有抗肿瘤活性的次黄嘌呤核苷酸脱氢酶抑制剂的研究进展 [J]. 中国药物化学杂志, 2021, 31(11): 901-910.
|
| 2 |
Zou J, Han Z, Zhou L, et al. Elevated expression of IMPDH2 is associated with progression of kidney and bladder cancer [J]. Med Oncol, 2015, 32(1): 373-384.
|
| 3 |
He Y, Zheng Z, Xu Y, et al. Over-expression of IMPDH2 is associated with tumor progression and poor prognosis in hepatocellular carcinoma [J]. Am J Cancer Res, 2018, 8(8): 1604-1614.
|
| 4 |
Xu Y, Zheng Z, Gao Y, et al. High expression of IMPDH2 is associated with aggressive features and poor prognosis of primary nasopharyngeal carcinoma [J]. Sci Rep, 2017, 7(1): 745-754.
|
| 5 |
Duan S, Huang W, Liu X, et al. IMPDH2 promotes colorectal cancer progression through activation of the PI3K/AKT/mTOR and PI3K/AKT/FOXO1 signaling pathways [J].J Exp Clin Cancer Res, 2018, 37(1): 304-315.
|
| 6 |
Li HX, Meng QP, Liu W, et al. IMPDH2 mediate radioresistance and chemoresistance in osteosarcoma cells [J].Eur Rev Med Pharmacol Sci, 2014, 18(20): 3038-3044.
|
| 7 |
Wang G, Wang F, Shan B et al. Uncovering potential genes in colorectal cancer based on integrated and DNA methylation analysis in the gene expression omnibus database [J]. BMC Cancer, 2022, 22(1): 138-139.
|
| 8 |
Cuny GD, Suebsuwong C, Ray SS. Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016) [J]. Expert Opin Ther Pat, 2017, 27(6): 677-690.
|
| 9 |
Carcamo WC, Satoh M, Kasahara H, et al. Induction of cytoplasmic rods and rings structures by inhibition of the CTP and GTP synthetic pathway in mammalian cells [J]. PLoS One, 2011, 6(12): e29690.
|
| 10 |
Hager PW, Collart FR, Huberman E, et al. Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Purification and characterization of inhibitor binding [J]. Biochem Pharmacol, 1995, 49(9): 1323-1329.
|
| 11 |
Wu Y, Wei X, Feng H, et al. An eleven metabolic gene signature-based prognostic model for clear cell renal cell carcinoma [J]. Aging (Albany NY), 2020, 12(22): 23165-23186.
|
| 12 |
Ruan H, Song Z, Cao Q, et al. IMPDH1/YB-1 positive feedback loop assembles cytoophidia and represents a therapeutic target in metastatic tumors [J]. Mol Ther, 2020, 28(5): 1299-1313.
|
| 13 |
Jia X, Liu Y, Cheng Y, et al. Inosine monophosphate dehydrogenase type1 sustains tumor growth in hepatocellular carcinoma [J].J Clin Lab Anal, 2022, 36(5): e24416.
|
| 14 |
Braun-Sand S B, Peetz M. Inosine monophosphate dehydrogenase as a target for antiviral, anticancer, antimicrobial and immunosuppressive therapeutics [J]. Future Medicinal Chemistry, 2010, 2(1): 81-92
|
| 15 |
Petrelli R, Vita P, Torquati I, et al. Novel inhibitors of inosine monophosphate dehydrogenase in patent literature of the last decade [J]. Recent Pat Anticancer Drug Discov, 2013, 8(2): 103-125.
|
| 16 |
Keppeke GD, Andrade LEC, Barcelos D, et al. IMPDH-based cytoophidium structures as potential theranostics in cancer [J].Mol Ther, 2020, 28(7): 1557-1558.
|
| 17 |
Tong X, Smith J, Bukreyeva N, et al. Merimepodib, an IMPDH inhibitor, suppresses replication of Zika virus and other emerging viral pathogens [J]. Antiviral Res, 2018, 9(14): 34-40.
|
| 18 |
Vanderlinden E, Marchand A, Van Berwaer R, et al. A broad influenza virus inhibitor acting via IMP dehydrogenase and in synergism with ribavirin [J]. Antiviral Res, 2021, 6(19): 105208-105209.
|
| 19 |
Mody K, Baldeo C, Bekaii-Saab T. Antiangiogenic therapy in colorectal cancer [J]. Cancer J, 2018, 24(4): 165-170.
|
| 20 |
Bhattacharya R, Fan F, Wang R, et al. Intracrine VEGF signalling mediates colorectal cancer cell migration and invasion [J]. Br J Cancer, 2017, 117(6): 848-855.
|
| 21 |
Ferreira PCL, Thiesen FV, Pereira AG, et al. A short overview on mycophenolic acid pharmacology and pharmacokinetics [J]. Clin Transplant, 2020, 34(8): e13997.
|
| 22 |
Chong CR, Qian DZ, Pan F, et al. Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target [J]. J Med Chem, 2006, 49(9): 2677-2680.
|
| 23 |
Valvezan AJ, McNamara MC, Miller SK, et al. IMPDH inhibitors for antitumor therapy in tuberous sclerosis complex [J]. JCI Insight, 2020, 5(7): e135071.
|
| 24 |
Keppeke GD, Andrade LEC, Barcelos D, et al. IMPDH-Based Cytooph- idium Structures as Potential Theranostics in Cancer [J]. Mol Ther, 2020, 28(7): 1557-1558.
|